1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014

Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014

  • December 2014
  • -
  • Global Markets Direct
  • -
  • 29 pages

Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct’s, ‘Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014’, provides an overview of the Bukwang Pharm.Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bukwang Pharm.Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Bukwang Pharm.Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Bukwang Pharm.Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Bukwang Pharm.Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Bukwang Pharm.Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Bukwang Pharm.Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Bukwang Pharm.Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Bukwang Pharm.Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bukwang Pharm.Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Bukwang Pharm.Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Bukwang Pharm.Co., Ltd. - Product Pipeline Review - 2014
Table of Contents
Bukwang Pharm.Co., Ltd. Snapshot 4
Bukwang Pharm.Co., Ltd. Overview 4
Key Information 4
Key Facts 4
Bukwang Pharm.Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Bukwang Pharm.Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Partnered Products 9
Partnered Products/Combination Treatment Modalities 10
Bukwang Pharm.Co., Ltd. - Pipeline Products Glance 11
Bukwang Pharm.Co., Ltd. - Late Stage Pipeline Products 11
Filing rejected/Withdrawn Products/Combination Treatment Modalities 11
Bukwang Pharm.Co., Ltd. - Clinical Stage Pipeline Products 12
Phase I Products/Combination Treatment Modalities 12
Bukwang Pharm.Co., Ltd. - Unknown Stage Pipeline Products 13
Unknown Products/Combination Treatment Modalities 13
Bukwang Pharm.Co., Ltd. - Drug Profiles 14
clevudine 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
YN-968D1 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
MLR-1023 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Bukwang Pharm.Co., Ltd. - Pipeline Analysis 20
Bukwang Pharm.Co., Ltd. - Pipeline Products by Target 20
Bukwang Pharm.Co., Ltd. - Pipeline Products by Route of Administration 21
Bukwang Pharm.Co., Ltd. - Pipeline Products by Molecule Type 22
Bukwang Pharm.Co., Ltd. - Pipeline Products by Mechanism of Action 23
Bukwang Pharm.Co., Ltd. - Recent Pipeline Updates 24
Bukwang Pharm.Co., Ltd. - Dormant Projects 25
Bukwang Pharm.Co., Ltd. - Discontinued Pipeline Products 26
Discontinued Pipeline Product Profiles 26
clevudine 26
Bukwang Pharm.Co., Ltd. - Locations And Subsidiaries 27
Head Office 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables

Bukwang Pharm.Co., Ltd., Key Information 4
Bukwang Pharm.Co., Ltd., Key Facts 4
Bukwang Pharm.Co., Ltd. - Pipeline by Indication, 2014 6
Bukwang Pharm.Co., Ltd. - Pipeline by Stage of Development, 2014 7
Bukwang Pharm.Co., Ltd. - Monotherapy Products in Pipeline, 2014 8
Bukwang Pharm.Co., Ltd. - Partnered Products in Pipeline, 2014 9
Bukwang Pharm.Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 10
Bukwang Pharm.Co., Ltd. - Filing rejected/Withdrawn, 2014 11
Bukwang Pharm.Co., Ltd. - Phase I, 2014 12
Bukwang Pharm.Co., Ltd. - Unknown, 2014 13
Bukwang Pharm.Co., Ltd. - Pipeline by Target, 2014 20
Bukwang Pharm.Co., Ltd. - Pipeline by Route of Administration, 2014 21
Bukwang Pharm.Co., Ltd. - Pipeline by Molecule Type, 2014 22
Bukwang Pharm.Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 23
Bukwang Pharm.Co., Ltd. - Recent Pipeline Updates, 2014 24
Bukwang Pharm.Co., Ltd. - Dormant Developmental Projects,2014 25
Bukwang Pharm.Co., Ltd. - Discontinued Pipeline Products, 2014 26

List of Figures

Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Indication, 2014 6
Bukwang Pharm.Co., Ltd. - Pipeline by Stage of Development, 2014 7
Bukwang Pharm.Co., Ltd. - Monotherapy Products in Pipeline, 2014 8
Bukwang Pharm.Co., Ltd. - Partnered Products in Pipeline, 2014 9
Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Target, 2014 20
Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014 21
Bukwang Pharm.Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014 22
Bukwang Pharm.Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Ophthalmology Drug Development Pipeline Review, 2016

Ophthalmology Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Ophthalmology Drug Development Pipeline Review, 2016 Summary Ophthalmology disorders are associated with the eyes and visual system. If left untreated, serious long-term co-morbidities such as diabetes, ...

Diabetes & Obesity Drug Development Pipeline Review, 2016

Diabetes & Obesity Drug Development Pipeline Review, 2016

  • $ 3995
  • Company report
  • December 2016
  • by GBI Research

Diabetes & Obesity Drug Development Pipeline Review, 2016 Summary The diabetes and obesity disease cluster is currently dominated by therapeutics indicated for type 1 diabetes mellitus (T1DM) and type ...

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

A Disintegrin And Metalloproteinase With Thrombospondin Motifs 5 (A Disintegrin And Metalloproteinase With Thrombospondin Motifs 11 or Aggrecanase 2 or ADMP2 or ADAMTS5 or EC 3.4.24.) - Pipeline Review, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.